Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures

Glioblastoma (GBM) heterogeneity, aggressiveness and infiltrative growth drastically limit success of current standard of care drugs and efficacy of various new therapeutic approaches. There is a need for new therapies and models reflecting the complex biology of these tumors to analyze the molecula...

Descripción completa

Detalles Bibliográficos
Autores principales: Alcaniz, Joshua, Winkler, Lars, Dahlmann, Mathias, Becker, Michael, Orthmann, Andrea, Haybaeck, Johannes, Krassnig, Stefanie, Skofler, Christina, Kratzsch, Tobias, Kuhn, Susanne A., Jödicke, Andreas, Linnebacher, Michael, Fichtner, Iduna, Walther, Wolfgang, Hoffmann, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126369/
https://www.ncbi.nlm.nih.gov/pubmed/37114125
http://dx.doi.org/10.3389/fonc.2023.1129627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126369/
https://www.ncbi.nlm.nih.gov/pubmed/37114125
http://dx.doi.org/10.3389/fonc.2023.1129627

Ejemplares similares